Origami Therapeutics announced a global collaboration with Ipsen to advance its protein degrader pipeline, focusing on targeted protein degradation modalities. The partnership gives Ipsen rights to develop and commercialize Origami’s degrader candidates and supports Origami’s acceleration of preclinical development and translational studies. The deal pairs Origami’s degrader platform expertise with Ipsen’s commercial and clinical development capabilities, aiming to move candidates toward the clinic more rapidly. Companies cited the therapeutic potential of degraders to target previously 'undruggable' proteins and said the collaboration will include joint development milestones and worldwide rights allocations.